BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
coupled to adjuvants, for pandemic and seasonal vaccine development
Industrial biotech and bioenergy: Focus is on the development of enzymes
with improved properties, including stability, specificity and catalytic
efficiency, as well as engineering cell lines to produce large amounts of
specialty and commodity chemicals from renewable feed stocks
Agriculture: Precision trait engineering, the enhancement of plant genetic
traits by engineering at the kilobase- to megabase-scale - more efficiently
than traditional breeding
PRODUCTS ON MARKET: Constructed clones and custom vectors
Constructed variant libraries
Constructed operons and operon variant libraries
Genomic engineering
CombiMatrix Corp.
6500 Harbour Heights Parkway, Suite 301
Mukilteo WA 98275, US
Phone: (425) 493-2000
Fax: (425) 493-2010
Toll-free phone: (800) 985-CBMX
Web: www.combimatrix.com
E-mail: info@combimatrix.com
KEY PERSONNEL: Amit Kumar, Ph.D.; President and CEO
Brooke Anderson, Ph.D.; COO
John Besser; CFO
Jeffrey Oster, Ph.D.; Sr. VP, Intellectual Property
Scott Burell; VP, Finance
H. Sho Fuji; VP, Engineering and Production
Andy McShea, Ph. D.; VP, Biology and Chemistry
EMPLOYEES: 95 employees
HISTORY: Incorporated in 1999
FACILITIES: Headquarters and R&D facilities in Mukilteo, Wash.
STOCK-FINANCIAL HISTORY: Privately held by parent (NASDAQ--CBMX)
SUBSIDIARIES/DIVISIONS: Acacia Technologies Group
CombiMatrix Molecular Diagnostics Inc.
SUBSIDIARY OF: Acacia Research Corp.
BUSINESS STRATEGY: Leverage strengths in technology, innovation and product development by
establishing partnerships for commercialization. CombiMatrix seeks
partnerships with organizations that have well-developed infrastructure for
manufacturing, sales and distribution. By combining the strengths of our
technologies with the distribution and manufacturing capabilities of partners,
CombiMatrix seeks to successfully develop and introduce industry-leading
products into the life science research, industrial and biothreat markets
AGREEMENTS: Name Products Content of Agreement Date
Benitec Ltd. Benitec IP related to cross-licensing and 2/05
pools of siRNAs as collaboration
therapeutic agents for
viral diseases,
CombiMatrix sequences
targeting HIV
agreement
BioDesign peptide array
development 8/05
Institute at Arizona
State University
synthesizer
agreement
Copyright ©2006 AHC Media ® 120